天大藥業(00455.HK)年度盈轉虧至2710萬港元
格隆匯6月25日丨天大藥業(00455.HK)公吿,截至2021年3月31日止年度全年業績,收入約為4.74億港元,同比減少3.5%。毛利率為54.6%(2020財政年度:73.5%),減少18.9個百分點。母公司股東應占虧損約為2710萬港元(2020財政年度:母公司股東應占溢利約310萬港元)。集團財務穩健,短期銀行存款及現金約為2億3500萬港元(2020年3月31日:約3億200萬港元)。董事會建議派付末期股息每股0.26港仙(2020財政年度:每股0.13港仙)。
集團遵循"以發展中醫藥產業為基礎,發展創新藥物和醫療科技,發展優質醫療和保健服務"的戰略,加大研發投入,加強產品開發和引進,並對接國家產業政策,加速全面推進中醫藥業務及醫療和保健服務的發展。為反映最新的業務發展,集團業務板塊重新界定和命名為中醫藥業務(前稱中醫業務)、藥物和醫療科技業務(前稱醫藥生物業務)、醫療和保健服務。中醫藥業務方面,收入從2020年3月31日止全年(2020財政年度)的約4,620萬港元大幅增加至2021年3月31日止年度(財政年度)的約1億1,200萬港元。
順應國家對中醫藥產業的支持政策,集團經過近五年的努力已基形成中醫藥全產業鏈佈局,涵蓋中藥材供應、中藥生產、中藥研發、中藥全產品線和國內外營銷。道地為源,專業為,標準先行,集團高度重視藥材和產品品質,建立起中藥材品質控制優於國家標準的“天大標準”,從根上確保中藥材品質可靠、可控、可追溯。並實施中藥材基地建設和經營貿易的策略,佈局全國主產區,拓展國內外市場,運用多種可行方式,實現和藥農、合作社、經銷商、藥企等夥伴的互惠合作,構建面向全國全球的中藥材業務網絡。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.